Targeted Oncology3d
What Is Dark Zone Lymphoma, and Is It Clinically Relevant?
Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...
Pharm Exec2d
FDA Approves AstraZeneca’s Calquence for Previously Untreated Mantle Cell Lymphoma
Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...
AstraZeneca lymphoma therapy Calquence gets expanded approval in the U.S.
AstraZeneca (NASDAQ:AZN) announced Friday that the U.S. FDA approved its Bruton’s tyrosine kinase (BTK) inhibitor Calquence ...
Healio2d
FDA approves therapies for colorectal cancer, mantle cell lymphoma
The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...
Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received 510(k) clearance from the United States Food and Drug ...
verywellhealth11d
Why Celiac Disease Significantly Raises Your Risk for Lymphoma
If you have celiac disease, you also likely have a higher-than-normal risk of developing non-Hodgkin lymphoma. This may seem frightening, and it's certainly something that you should take ...
Monthly Prescribing Reference2d
Calquence Combo Therapy Approved for Previously Untreated Mantle Cell Lymphoma
The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...